These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34156985)

  • 1. KRAS-driven model of Gorham-Stout disease effectively treated with trametinib.
    Homayun-Sepehr N; McCarter AL; Helaers R; Galant C; Boon LM; Brouillard P; Vikkula M; Dellinger MT
    JCI Insight; 2021 Aug; 6(15):. PubMed ID: 34156985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trametinib inhibits lymphatic vessel invasion of bone in a mouse model of Gorham-Stout disease.
    McCarter AL; Dellinger MT
    J Vasc Anom (Phila); 2023 Dec; 4(4):. PubMed ID: 38737531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A somatic activating KRAS variant identified in an affected lesion of a patient with Gorham-Stout disease.
    Nozawa A; Ozeki M; Niihori T; Suzui N; Miyazaki T; Aoki Y
    J Hum Genet; 2020 Nov; 65(11):995-1001. PubMed ID: 32591603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function.
    Fernandes LM; Tresemer J; Zhang J; Rios JJ; Scallan JP; Dellinger MT
    Front Cell Dev Biol; 2023; 11():1276333. PubMed ID: 37842094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
    Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
    Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF-C promotes the development of lymphatics in bone and bone loss.
    Hominick D; Silva A; Khurana N; Liu Y; Dechow PC; Feng JQ; Pytowski B; Rutkowski JM; Alitalo K; Dellinger MT
    Elife; 2018 Apr; 7():. PubMed ID: 29620526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 8. Viewpoints on vessels and vanishing bones in Gorham-Stout disease.
    Dellinger MT; Garg N; Olsen BR
    Bone; 2014 Jun; 63():47-52. PubMed ID: 24583233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced expression of semaphorin 3A in osteoclasts causes lymphatic expansion in a Gorham-Stout disease (GSD) mouse model.
    Zhang D; Xu H; Qin C; Cai K; Zhang J; Xia X; Bi J; Zhang L; Xing L; Liang Q; Wang W
    J Zhejiang Univ Sci B; 2024 Jan; 25(1):38-50. PubMed ID: 38163665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex Lymphatic Anomalies: Report on a Patient Registry Using the Latest Diagnostic Guidelines.
    Andreoti TA; Berg S; Holm A; Angerer M; Oberlin M; Foeldi E; Baumgartner I; Niemeyer CM; Rössler J; Kapp FG
    Lymphat Res Biol; 2023 Jun; 21(3):230-243. PubMed ID: 36706428
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice.
    Park ES; Kim S; Huang S; Yoo JY; Körbelin J; Lee TJ; Kaur B; Dash PK; Chen PR; Kim E
    Ann Neurol; 2021 May; 89(5):926-941. PubMed ID: 33675084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gorham-Stout disease and generalized lymphatic anomaly--clinical, radiologic, and histologic differentiation.
    Lala S; Mulliken JB; Alomari AI; Fishman SJ; Kozakewich HP; Chaudry G
    Skeletal Radiol; 2013 Jul; 42(7):917-24. PubMed ID: 23371338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
    Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
    Dai X; Xia H; Zhou S; Tang Q; Bi F
    Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gorham-Stout disease: radiological, histological, and clinical features of 12 cases and review of literature.
    Liu Y; Zhong DR; Zhou PR; Lv F; Ma DD; Xia WB; Jiang Y; Wang O; Xing XP; Li M
    Clin Rheumatol; 2016 Mar; 35(3):813-23. PubMed ID: 25227772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
    Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
    Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.
    Allegrezza MJ; Rutkowski MR; Stephen TL; Svoronos N; Perales-Puchalt A; Nguyen JM; Payne KK; Singhal S; Eruslanov EB; Tchou J; Conejo-Garcia JR
    Cancer Res; 2016 Nov; 76(21):6253-6265. PubMed ID: 27803104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone development and fracture healing is normal in mice that have a defect in the development of the lymphatic system.
    McCarter AL; Khalid A; Yi Y; Monroy M; Zhao H; Rios JJ; Dellinger MT
    Lymphology; 2020; 53(4):162-171. PubMed ID: 33721923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.